BCRX Financial Facts

Loss on foreign currency derivative: 4.08M
Basic and diluted net loss per common share: -0.12
See Full Income Statement

Total stockholders' equity: 83.45M
Cash and cash equivalents: 121.16M
See Full Balance Sheet

BioCryst Pharmaceuticals, Inc. (BCRX) Earnings

  |   Expand Research on BCRX
Next EPS Date 5/8/15 *Est. EPS Growth Rate -77.8% *Last Qtr.
Average EPS % Beat Rate +10.7% Revenue Growth Rate -49.1% *Last Qtr.
Average % Move 1-Wk after EPS +0.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/18/15 Q414 -$0.16-$0.21 +$0.05$5.4M$3.64M N/A Details
11/6/14 Q314 -$0.12-$0.20 +$0.08$3.2M$2.11M N/A Details
8/5/14 Q214 -$0.23-$0.19 -$0.04$1.5M$2.32M N/A Details
5/8/14 Q114 -$0.17-$0.17 $0.00N/A$3.34M N/A Details
2/26/14 Q413 -$0.09-$0.08 -$0.01$10.6M$8.81M N/A Details
11/5/13 Q313 -$0.14-$0.14 $0.00$2.4M$2.01M N/A Details
8/8/13 Q213 -$0.23-$0.14 -$0.09$821K$2.01M N/A Details
5/7/13 Q113 -$0.09-$0.15 +$0.06$3.6M$1.31M N/A Details